SMi’s 3rd annual Immunogenicity will be returning to Holiday Inn Kensington Forum, London, UK on 13-14 June 2016
LONDON, UNITED KINGDOM, May 27, 2016 /EINPresswire.com/ — Immunogenicity 2016 will discuss hot industry topics such as integration of immunogenicity risk data to forecast clinical outcomes, personalized cancer vaccine development and much more.
SMi Group reports: Annie De Groot, CEO, EpiVax will be presenting on day 2 of the event on: “A computational pipeline for personalised cancer vaccine development”. Annie De Groot will be discussing how checkpoint inhibitors are changing cure rates for cancer and generating excitement in the cancer field. Participants will learn how personalised cancer vaccines will move the needle on cancer cures of the future.